Smart Immune SAS
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2017-07-17
- Employees
- 11
- Market Cap
- -
- Website
- http://www.smart-immune.com
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Phase 1
Recruiting
- Conditions
- Hematological Malignancies
- Interventions
- Biological: Allogeneic T cell progenitors, cultured ex-vivo
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Smart Immune SAS
- Target Recruit Count
- 40
- Registration Number
- NCT05768035
- Locations
- 🇫🇷
Centre hospitalier universitaire de Nantes, Nantes, France
🇫🇷Institut Paoli Calmettes, Marseille, France
🇫🇷Hôpital Saint-Louis, Paris, France
Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors
Not Applicable
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Procedure: Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Smart Immune SAS
- Target Recruit Count
- 14
- Registration Number
- NCT05118113
- Locations
- 🇫🇷
CIC Paris Est, Hôpital Pitié Salpêtrière, Paris, France
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Phase 1
Recruiting
- Conditions
- Hematological Malignancies
- Interventions
- Biological: Allogeneic T cell progenitors, cultured ex-vivo
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Smart Immune SAS
- Target Recruit Count
- 36
- Registration Number
- NCT04959903
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath